Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H20N4O2.2C2H6O4S |
Molecular Weight | 564.63 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCS(O)(=O)=O.OCCS(O)(=O)=O.NC(=N)C1=CC=C(OCCCOC2=CC=C(C=C2)C(N)=N)C=C1
InChI
InChIKey=WSOSYBUSMXEYDO-UHFFFAOYSA-N
InChI=1S/C17H20N4O2.2C2H6O4S/c18-16(19)12-2-6-14(7-3-12)22-10-1-11-23-15-8-4-13(5-9-15)17(20)21;2*3-1-2-7(4,5)6/h2-9H,1,10-11H2,(H3,18,19)(H3,20,21);2*3H,1-2H2,(H,4,5,6)
Molecular Formula | C2H6O4S |
Molecular Weight | 126.132 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C17H20N4O2 |
Molecular Weight | 312.3663 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Propamidine, an aromatic diamidine compound, is widely used as an antimicrobial agent. Propamidine isethionate, the salt of propamidine with isethionic acid, is used in the treatment of Acanthamoeba infection. Diseases caused by Acanthamoeba include keratitis and granulomatous amoebic encephalitis.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia. | 1990 Apr |
|
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
Structure-in vitro activity relationships of pentamidine analogues and dication-substituted bis-benzimidazoles as new antifungal agents. | 1998 Oct |
|
[Painless acanthamoeba keratitis]. | 2001 Aug |
|
Aromatic polyamidines inhibiting the Tat-induced HIV-1 transcription recognize structured TAR-RNA. | 2001 Aug |
|
Encystation in Acanthamoeba castellanii: development of biocide resistance. | 2001 Jan-Feb |
|
Persistence of a clone of methicillin-resistant Staphylococcus aureus in a burns unit. | 2001 Jun |
|
Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals. | 2001 Mar |
|
Genetic analysis of methicillin-resistant Staphylococcus aureus expressing high- and low-level mupirocin resistance. | 2001 Oct |
|
Atypical presentation of Acanthamoeba keratitis. | 2001 Oct |
|
[Acanthamoeba keratitis, a possible dibromo propamidine isethionate resistance]. | 2002 May |
|
[Treatment of Acanthamoeba keratitis: possibilities, problems, and new approaches]. | 2003 |
|
Persistently culture positive acanthamoeba keratitis: in vivo resistance and in vitro sensitivity. | 2003 Aug |
|
Bilateral microsporidial keratoconjunctivitis in an immunocompetent non-contact lens wearer. | 2003 May |
|
A chromosomal location of the mupA gene in Staphylococcus aureus expressing high-level mupirocin resistance. | 2003 May |
|
Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. | 2003 Oct |
|
Persistent acanthamoeba keratitis in a non-contact lens wearer following exposure to bird seed dust. | 2005 Mar |
|
Acanthamoeba keratitis associated with misuse of daily disposable contact lenses. | 2006 Dec |
|
Good visual outcome after prompt treatment of acanthamoeba keratitis associated with overnight orthokeratology lens wear. | 2007 Nov |
|
Bilateral acanthamoeba keratitis. | 2008 Feb |
|
Prognostic factors affecting visual outcome in Acanthamoeba keratitis. | 2008 Nov |
|
Phenotypic and molecular characterization of Staphylococcus aureus isolates expressing low- and high-level mupirocin resistance in Nigeria and South Africa. | 2009 Jan 28 |
Patents
Sample Use Guides
1-2 drops in the affected eye 3-4 times daily, for not more than 1 week
Route of Administration:
Topical
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/8985640
There was compared the amoebicidal activity of the Brolene (propamidine isethionate, commercial product), propamidine isethionate and pentamidine isethionate (Pentam) in vitro against three different species of Acanthamoeba, and the drugs' corresponding biocompatibility with rabbit corneal epithelial and endothelial cell cultures. The results indicated that there were significant species differences in drug sensitivity. Propamidine (> 1,000 micrograms/ml) was clearly less effective than pentamidine (> 125 micrograms/ml) against A. castellanii, although equivalent potency (> 250 micrograms/ml) was observed against A. polyphaga. On the other hand, propamidine (> 31.25 micrograms/ml) was slightly more effective than pentamidine (> 62.5 micrograms/ml) against A. hatchetti.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:58:42 GMT 2023
by
admin
on
Fri Dec 15 15:58:42 GMT 2023
|
Record UNII |
7T9IJ84C42
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
27288
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000092322
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
SUB04079MIG
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
140-63-6
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
87175
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
34634
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | RxNorm | ||
|
7T9IJ84C42
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
m9181
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | Merck Index | ||
|
C046651
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
205-423-6
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
DTXSID50161211
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
Propamidine isethionate
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY | |||
|
67413
Created by
admin on Fri Dec 15 15:58:42 GMT 2023 , Edited by admin on Fri Dec 15 15:58:42 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |